drugset / Trial / NCT06626464

A Study of Elpipodect (MK-8189) Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8189-010)

NCT06626464

Phase 1 Completed 6 enrolled Merck Sharp & Dohme LLC
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to learn what happens to elpipodect in a healthy person's body over time.

Timeline

Start
2022-05-13
Primary completion
2022-07-08
Completion
2022-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-8189 Small molecule 4.5 mg Oral

Indications

No indication recorded.